Iron deficiency anaemia in adolescent athletes of the Vila Olímpica Fonndation of Manaus - AM

Considering the dearth of information with regard to the nutritional state of young athletes, were identified the prevalence of iron deficiency anaemia and its association with nutritional indicators of adolescent athletes participating in the Sport Initiation Program of the Vila Olímpica Foundation in Manaus -AM. A sample was made up of 194 voluntary adolescent male athletes classified as beginners, who participated in several different sports. Data collected was by verification of anthropometric measures (body weight, height, and skinfold thicknesses of triceps and subscapular skinfold), hemoglobin dosage utilizing a portable hemoglobinometer, HemoCue direct calorimetric method, and socioeconomic instrument. In the diagnosis of the nutritional states, we used Height-for-age- and Body Mass Index for the age indicators, adjusted cut-off points proposed by the WHO. The results showed that 9.4 % of the adolescents suffered from malnutrition, 8.2% overweight, and 4.6 obesity. The prevalence of iron deficiency anaemia found in the samples was 41.7%, with predominance in the lowest socioeconomic class. Although the prevalence of anaemia was high, the nutritional state of the adolescents did not influence these results, considering that the majority looked healthy. In view of these findings, we suggest that effective means be taken for nutritional education to minimize and/or control iron deficiency anaemia.Considerando a escassez de informações quanto ao estado nutricional de atletas jovens, identificou-se a prevalência de anemia ferropriva e sua associação com indicadores nutricionais de atletas adolescentes participantes do Programa de Iniciação Esportiva da Fundação Vila Olímpica de Manaus-AM. A amostra foi constituída por 194 atletas adolescentes do gênero masculino, voluntários, praticantes de diferentes modalidades esportivas classificados como iniciantes. A coleta dos dados foi realizada mediante verificação de medidas antropométricas (peso corporal, estatura e espessuras das dobras cutâneas tricipital e subescapular), dosagem de hemoglobina utilizando o hemoglobinômetro portátil (Sistema Hemocue) e instrumento socioeconômico. No diagnóstico do estado nutricional foram utilizados os indicadores Estatura para a Idade (E/I) e Índice de Massa Corporal para a idade (IMC/I), assumindo pontos de corte propostos pela OMS. Os resultados mostraram que 9,4% dos adolescentes apresentaram desnutrição, 8,2% sobrepeso e 4,6% obesidade. A prevalência de anemia ferropriva encontrada na amostra foi de 41,7%, com predominância na classe socioeconômica mais baixa. Embora a prevalência de anemia tenha sido elevada, o estado nutricional dos adolescentes não influenciou sobre este resultado, considerando que a maioria dos adolescentes apresentou-se eutrófica. Diante do exposto, sugere-se a adoção de medidas efetivas de intervenção e de educação nutricional visando à minimização e/ou o controle da anemia ferropriva

Glicemia e concentrações séricas de insulina, triglicérides e cortisol em equinos da raça Mangalarga Marchador após exercício físico

O presente estudo teve por objetivo avaliar a influência do exercício físico de intensidade submáxima (provas de marcha) sobre as variáveis bioquímicas sanguíneas usadas na avaliação do metabolismo energético em equinos da raça Mangalarga Marchador criados no Estado do Espírito Santo. Para tal foram obtidas amostras de soro e plasma de 15 equinos, da raça Mangalarga Marchador, em quatro momentos assim definidos: antes (T0) e com 5 minutos (T1), 30 minutos (T2) e 2 horas (T3) após o término do exercício. A análise dos resultados demonstrou a não influência do exercício físico imposto sobre a glicose plasmática, com valores médios de 117,1±35,8mg/dL, 122,6±59,6mg/dL, 124,8± 48,6mg/dL e 112,9±49,1mg/dL, e sobre a insulina sérica, com valores de mediana de 6,50mUI/mL, 2,00mUI/mL, 5,85mUI/mL e 11,60mUI/mL, respectivamente, nos tempos T0, T1, T2 e T3. De forma oposta, foi possível observar uma influência significativa sobre triglicérides séricos, com valores médios de 25,4±14,9mg/dL, 42,3±17,8mg/dL, 31,4±17,7mg/dL e 25,1±15,1mg/dL, e sobre o cortisol sérico, com valores médios de 7,46±4,37mg/dL, 12,45±3,08mg/dL, 11,40±2,52mg/dL e 6,89±1,78mg/dL, respectivamente nos tempos T0, T1, T2 e T3. A interpretação destes resultados permitiu concluir que a marcha elevou as concentrações séricas de triglicérides e cortisol. Também foi possível destacar que, por tais valores encontrarem-se dentro de intervalos fisiológicos, os equinos usados estavam aptos ao nível de exercício físico imposto na ocasião

Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

Background: Sleep disturbance is common following hospital admission both for COVID-19 and other causes. The clinical associations of this for recovery after hospital admission are poorly understood despite sleep disturbance contributing to morbidity in other scenarios. We aimed to investigate the prevalence and nature of sleep disturbance after discharge following hospital admission for COVID-19 and to assess whether this was associated with dyspnoea. Methods: CircCOVID was a prospective multicentre cohort substudy designed to investigate the effects of circadian disruption and sleep disturbance on recovery after COVID-19 in a cohort of participants aged 18 years or older, admitted to hospital for COVID-19 in the UK, and discharged between March, 2020, and October, 2021. Participants were recruited from the Post-hospitalisation COVID-19 study (PHOSP-COVID). Follow-up data were collected at two timepoints: an early time point 2–7 months after hospital discharge and a later time point 10–14 months after hospital discharge. Sleep quality was assessed subjectively using the Pittsburgh Sleep Quality Index questionnaire and a numerical rating scale. Sleep quality was also assessed with an accelerometer worn on the wrist (actigraphy) for 14 days. Participants were also clinically phenotyped, including assessment of symptoms (ie, anxiety [Generalised Anxiety Disorder 7-item scale questionnaire], muscle function [SARC-F questionnaire], dyspnoea [Dyspnoea-12 questionnaire] and measurement of lung function), at the early timepoint after discharge. Actigraphy results were also compared to a matched UK Biobank cohort (non-hospitalised individuals and recently hospitalised individuals). Multivariable linear regression was used to define associations of sleep disturbance with the primary outcome of breathlessness and the other clinical symptoms. PHOSP-COVID is registered on the ISRCTN Registry (ISRCTN10980107). Findings: 2320 of 2468 participants in the PHOSP-COVID study attended an early timepoint research visit a median of 5 months (IQR 4–6) following discharge from 83 hospitals in the UK. Data for sleep quality were assessed by subjective measures (the Pittsburgh Sleep Quality Index questionnaire and the numerical rating scale) for 638 participants at the early time point. Sleep quality was also assessed using device-based measures (actigraphy) a median of 7 months (IQR 5–8 months) after discharge from hospital for 729 participants. After discharge from hospital, the majority (396 [62%] of 638) of participants who had been admitted to hospital for COVID-19 reported poor sleep quality in response to the Pittsburgh Sleep Quality Index questionnaire. A comparable proportion (338 [53%] of 638) of participants felt their sleep quality had deteriorated following discharge after COVID-19 admission, as assessed by the numerical rating scale. Device-based measurements were compared to an age-matched, sex-matched, BMI-matched, and time from discharge-matched UK Biobank cohort who had recently been admitted to hospital. Compared to the recently hospitalised matched UK Biobank cohort, participants in our study slept on average 65 min (95% CI 59 to 71) longer, had a lower sleep regularity index (–19%; 95% CI –20 to –16), and a lower sleep efficiency (3·83 percentage points; 95% CI 3·40 to 4·26). Similar results were obtained when comparisons were made with the non-hospitalised UK Biobank cohort. Overall sleep quality (unadjusted effect estimate 3·94; 95% CI 2·78 to 5·10), deterioration in sleep quality following hospital admission (3·00; 1·82 to 4·28), and sleep regularity (4·38; 2·10 to 6·65) were associated with higher dyspnoea scores. Poor sleep quality, deterioration in sleep quality, and sleep regularity were also associated with impaired lung function, as assessed by forced vital capacity. Depending on the sleep metric, anxiety mediated 18–39% of the effect of sleep disturbance on dyspnoea, while muscle weakness mediated 27–41% of this effect. Interpretation: Sleep disturbance following hospital admission for COVID-19 is associated with dyspnoea, anxiety, and muscle weakness. Due to the association with multiple symptoms, targeting sleep disturbance might be beneficial in treating the post-COVID-19 condition. Funding: UK Research and Innovation, National Institute for Health Research, and Engineering and Physical Sciences Research Council

Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury

A proportion of patients infected with severe acute respiratory syndrome coronavirus 2 experience a range of neuropsychiatric symptoms months after infection, including cognitive deficits, depression and anxiety. The mechanisms underpinning such symptoms remain elusive. Recent research has demonstrated that nervous system injury can occur during COVID-19. Whether ongoing neural injury in the months after COVID-19 accounts for the ongoing or emergent neuropsychiatric symptoms is unclear. Within a large prospective cohort study of adult survivors who were hospitalized for severe acute respiratory syndrome coronavirus 2 infection, we analysed plasma markers of nervous system injury and astrocytic activation, measured 6 months post-infection: neurofilament light, glial fibrillary acidic protein and total tau protein. We assessed whether these markers were associated with the severity of the acute COVID-19 illness and with post-acute neuropsychiatric symptoms (as measured by the Patient Health Questionnaire for depression, the General Anxiety Disorder assessment for anxiety, the Montreal Cognitive Assessment for objective cognitive deficit and the cognitive items of the Patient Symptom Questionnaire for subjective cognitive deficit) at 6 months and 1 year post-hospital discharge from COVID-19. No robust associations were found between markers of nervous system injury and severity of acute COVID-19 (except for an association of small effect size between duration of admission and neurofilament light) nor with post-acute neuropsychiatric symptoms. These results suggest that ongoing neuropsychiatric symptoms are not due to ongoing neural injury

Accelarated immune ageing is associated with COVID-19 disease severity

Background The striking increase in COVID-19 severity in older adults provides a clear example of immunesenescence, the age-related remodelling of the immune system. To better characterise the association between convalescent immunesenescence and acute disease severity, we determined the immune phenotype of COVID-19 survivors and non-infected controls. Results We performed detailed immune phenotyping of peripheral blood mononuclear cells isolated from 103 COVID-19 survivors 3–5 months post recovery who were classified as having had severe (n = 56; age 53.12 ± 11.30 years), moderate (n = 32; age 52.28 ± 11.43 years) or mild (n = 15; age 49.67 ± 7.30 years) disease and compared with age and sex-matched healthy adults (n = 59; age 50.49 ± 10.68 years). We assessed a broad range of immune cell phenotypes to generate a composite score, IMM-AGE, to determine the degree of immune senescence. We found increased immunesenescence features in severe COVID-19 survivors compared to controls including: a reduced frequency and number of naïve CD4 and CD8 T cells (p < 0.0001); increased frequency of EMRA CD4 (p < 0.003) and CD8 T cells (p < 0.001); a higher frequency (p < 0.0001) and absolute numbers (p < 0.001) of CD28−ve CD57+ve senescent CD4 and CD8 T cells; higher frequency (p < 0.003) and absolute numbers (p < 0.02) of PD-1 expressing exhausted CD8 T cells; a two-fold increase in Th17 polarisation (p < 0.0001); higher frequency of memory B cells (p < 0.001) and increased frequency (p < 0.0001) and numbers (p < 0.001) of CD57+ve senescent NK cells. As a result, the IMM-AGE score was significantly higher in severe COVID-19 survivors than in controls (p < 0.001). Few differences were seen for those with moderate disease and none for mild disease. Regression analysis revealed the only pre-existing variable influencing the IMM-AGE score was South Asian ethnicity ( = 0.174, p = 0.043), with a major influence being disease severity ( = 0.188, p = 0.01). Conclusions Our analyses reveal a state of enhanced immune ageing in survivors of severe COVID-19 and suggest this could be related to SARS-Cov-2 infection. Our data support the rationale for trials of anti-immune ageing interventions for improving clinical outcomes in these patients with severe disease

Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

Introduction: The multiorgan impact of moderate to severe coronavirus infections in the post-acute phase is still poorly understood. We aimed to evaluate the excess burden of multiorgan abnormalities after hospitalisation with COVID-19, evaluate their determinants, and explore associations with patient-related outcome measures. Methods: In a prospective, UK-wide, multicentre MRI follow-up study (C-MORE), adults (aged ≥18 years) discharged from hospital following COVID-19 who were included in Tier 2 of the Post-hospitalisation COVID-19 study (PHOSP-COVID) and contemporary controls with no evidence of previous COVID-19 (SARS-CoV-2 nucleocapsid antibody negative) underwent multiorgan MRI (lungs, heart, brain, liver, and kidneys) with quantitative and qualitative assessment of images and clinical adjudication when relevant. Individuals with end-stage renal failure or contraindications to MRI were excluded. Participants also underwent detailed recording of symptoms, and physiological and biochemical tests. The primary outcome was the excess burden of multiorgan abnormalities (two or more organs) relative to controls, with further adjustments for potential confounders. The C-MORE study is ongoing and is registered with ClinicalTrials.gov, NCT04510025. Findings: Of 2710 participants in Tier 2 of PHOSP-COVID, 531 were recruited across 13 UK-wide C-MORE sites. After exclusions, 259 C-MORE patients (mean age 57 years [SD 12]; 158 [61%] male and 101 [39%] female) who were discharged from hospital with PCR-confirmed or clinically diagnosed COVID-19 between March 1, 2020, and Nov 1, 2021, and 52 non-COVID-19 controls from the community (mean age 49 years [SD 14]; 30 [58%] male and 22 [42%] female) were included in the analysis. Patients were assessed at a median of 5·0 months (IQR 4·2–6·3) after hospital discharge. Compared with non-COVID-19 controls, patients were older, living with more obesity, and had more comorbidities. Multiorgan abnormalities on MRI were more frequent in patients than in controls (157 [61%] of 259 vs 14 [27%] of 52; p5mg/L, OR 3·55 [1·23–11·88]; padjusted=0·025) than those without multiorgan abnormalities. Presence of lung MRI abnormalities was associated with a two-fold higher risk of chest tightness, and multiorgan MRI abnormalities were associated with severe and very severe persistent physical and mental health impairment (PHOSP-COVID symptom clusters) after hospitalisation. Interpretation: After hospitalisation for COVID-19, people are at risk of multiorgan abnormalities in the medium term. Our findings emphasise the need for proactive multidisciplinary care pathways, with the potential for imaging to guide surveillance frequency and therapeutic stratification. Funding: UK Research and Innovation and National Institute for Health Research